[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Guangzhou Concord Cancer Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":124},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,72,96],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100624645","prospective-phase-ii-clinical-study-of-stereotactic-body-proton-therapy-sbpt-for-lung-cancer-100624645",false,"NCT07412327","Prospective Phase II Clinical Study of Stereotactic Body Proton Therapy (SBPT) for Lung Cancer","A Single-Center, Prospective Phase II Clinical Study of Stereotactic Body Proton Therapy (SBPT) for Early-Stage Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n1. .Lung cancer confirmed by histology and\u002For cytology; and in the absence of pathological diagnosis, patients who meet the following conditions can also be included: diagnosed by more than 2 imaging modalities, and the clinical diagnosis of lung cancer is confirmed after multidisciplinary team (MDT) discussion.\n2. The clinical staging based on positron emission tomography(PET)-computer tomography(CT) examination is: cT1\\~3 N0M0, stage IA-IIB (AJCC eighth edition).\n3. Age: 18 years and above.\n4. Karnofsky(KPS) score ≥60.\n5. The doctor assesses that surgical treatment is not suitable or the patient refuses surgery.\n6. Relatively good organ function:\n7. Normal bone marrow function: white blood cell (WBC)≥3×109\u002FL, Platelet ≥80×109\u002FL, Hemoglobin(HGB)≥90g\u002FL\n8. Normal liver and kidney function:\n9. Total bilirubin, Aspartate Aminotransferase(AST), and ALT(Alanine Aminotransferase)≤2.0×upper limit of normal values;\n10. Creatinine clearance ≥60ml\u002Fmin or creatinine ≤1.5×upper limit of normal value\n11. The patient has signed an informed consent form and is willing and able to comply with planned study visits, treatment plans, laboratory tests, and other study procedures.\n\nExclusion Criteria:\n\n1. Patients with other malignant tumors.\n2. Poorly controlled heart failure, respiratory failure, heart function, and lung function below grade 3 (including grade 3).\n3. Those whose laboratory test values do not meet relevant standards before enrollment.\n4. Patients who cannot cooperate with regular follow-up due to psychological, social, family and geographical reasons.\n5. Women of childbearing age who have a positive pregnancy test and women who are breastfeeding.\n6. Patients considered inappropriate for inclusion by other investigators.","ALL","18 Years",{"count":19,"type":20},65,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study included patients with early-stage lung cancer cT1-3N0M0, stage IA-IIB (American Joint Committee on Cancer eighth edition staging, AJCC 8th ) who were inoperable or refused surgery. They were divided into peripheral type and central type according to the tumor location and received radical Stereotactic Body Proton Therapy (SBPT) for Early-Stage Non-Small Cell Lung Cancer. The prescribed dose for patients with peripheral lung cancer is 48-60Gray(Gy) (Relative Biological Effectiveness, RBE)\u002F4-6 fractions, and for patients with central lung cancer, the prescribed dose is 50-70Gy(RBE)\u002F10-15 fractions. After treatment, follow-up visits will be conducted to observe short-term and long-term efficacy, adverse reactions and patient quality of life.",[26,27],"Early-Stage Lung Cancer","Lung Cancer",[29,30,31,26,32,33],"Proton therapy","hypofractionated radiotherapy","radiotherapy","lung cancer","SBPT","RECRUITING","2026-05-19",{"date":37,"type":38},"2026-05-22","ACTUAL",{"date":40,"type":38},"2026-02-24",{"date":42,"type":20},"2029-07-01",{"name":44,"class":45},"Guangzhou Concord Cancer Center","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":4},"100638676","a-multicenter-prospective-phase-iii-clinical-study-of-proton-intensity-modulated-radiotherapy-versus-photon-intensity-modulated-radiotherapy-for-untreated-non-metastatic-nasopharyngeal-carcinoma-100638676","NCT07578727","A Multicenter, Prospective, Phase III Clinical Study of Proton Intensity-modulated Radiotherapy Versus Photon Intensity-modulated Radiotherapy for Untreated Non-metastatic Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n1. Diagnosed by histology and\u002For cytology as non-keratinizing carcinoma of the nasopharynx (differentiated or undifferentiated type, i.e., WHO type II or III).\n2. Clinical stage: T1-4N0-3M0, I-III stage (AJCC 9th edition).\n3. Age: ≥ 18 years old, ≤ 70 years old.\n4. Gender: No restrictions.\n5. ECOG ≤ 1.\n6. Good organ function:\n\n   Normal bone marrow function: WBC ≥ 4×109\u002FL, Platelet ≥ 100×109\u002FL, HGB ≥ 90g\u002FL Total bilirubin, AST, ALT ≤ 2.0× upper limit of normal value; Creatinine clearance rate ≥ 60ml\u002Fmin or Creatinine ≤ 1.5× upper limit of normal value.\n7. The patient has signed the informed consent form and is willing and able to comply with the study visit schedule, treatment plan, laboratory tests and other research procedures.\n\nExclusion Criteria:\n\n1. The patient has a poor general condition and is in a state of poor health; or the patient has already experienced metastasis.\n2. The patient has an uncontrolled severe infectious disease.\n3. The patient has severe diseases or complications in the heart, lungs, liver, kidneys or other systems, and the investigator judges that they cannot complete the clinical trial.\n4. There are implants such as artificial ears or dentures within the radiotherapy range, and the investigator judges that they are not suitable for proton therapy.\n5. The patient has a history of radiotherapy in the head and neck region.\n6. The patient has mental illness, drug abuse or alcohol dependence.","70 Years",{"count":55,"type":20},504,[23],"Proton therapy for nasopharyngeal carcinoma can reduce radiotherapy-related toxic reactions, and some retrospective studies have found that proton therapy improves the survival of patients with nasopharyngeal carcinoma. However, high-level prospective clinical evidence is still lacking. This study aims to investigate the efficacy and side effects of proton therapy compared with photon intensity-modulated radiotherapy for nasopharyngeal carcinoma through a multicenter, prospective, phase III clinical trial, providing more high-quality evidence-based medical evidence for proton therapy of nasopharyngeal carcinoma.",[59],"Nasopharyngeal Carcinoma (NPC)",[61,62],"proton therapy","nasopharyngeal carcinoma","NOT_YET_RECRUITING","2026-05-13",{"date":66,"type":38},"2026-05-15",{"date":68,"type":20},"2026-05-01",{"date":70,"type":20},"2028-12-30",{"name":44,"class":45},{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":21,"phases":81,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},"100624644","proton-therapy-for-recurrent-nasopharyngeal-carcinoma-100624644","NCT07412314","Proton Therapy for Recurrent Nasopharyngeal Carcinoma","A Prospective Phase II Clinical Study of Proton Therapy for Recurrent Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n1. Non-metastatic squamous cell carcinoma of the nasopharynx with biopsy confirmation, at stage ≥ T2b and\u002For with positive lymph nodes, (2) Pathological type WHO I-III\n2. PS score (according to Eastern Cooperative Oncology Group (ECOG) standard) 0-1.\n\n   Age ≥ 18 years.\n3. Expected survival period ≥ 6 months\n4. Before treatment, evaluate the tumor range and size of the patient.\n5. Nutritional and general physical condition must be able to tolerate the recommended radiotherapy and chemotherapy.\n\nExclusion Criteria:\n\n1. Evidence of distant metastasis in stage IVc\n2. Patients with isolated recurrence of cervical lymph nodes;\n3. Patients have participated in other interventional trials for tumors\n4. Having suffered from other malignant tumors within 5 years (excluding melanoma skin cancer) or tumors originating from the head and neck region Untreated active infections",{"count":80,"type":20},52,[23],"The above studies show that most of the supportive evidence for the reduction of toxicity and improvement of efficacy of proton therapy for recurrent Nasopharyngeal carcinoma(NPC) comes from various observational and retrospective studies, lacking high-level evidence-based medical evidence. The conduct of this study will explore the safety and efficacy of intensity-modulated proton radiotherapy for recurrent NPC and provide more high-quality evidence-based medical evidence for proton therapy of recurrent cancer.",[84],"Recurrent Nasopharyngeal Carcinoma",[61,86],"recurrent nasopharyngeal carcinoma","2026-03-05",{"date":89,"type":38},"2026-03-09",{"date":91,"type":38},"2025-03-10",{"date":93,"type":20},"2028-03-10",{"name":44,"class":45},2,{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":21,"phases":106,"briefSummary":107,"conditions":108,"keywords":110,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":46},"100537827","effects-of-music-therapy-on-psychological-states-among-cancer-patients-undergoing-mri-scans-and-a-relevant-mediator-100537827","NCT06282887","Effects of Music Therapy on Psychological States Among Cancer Patients Undergoing MRI Scans and a Relevant Mediator","The Effects of Music Therapy on Improving Psychological States of Cancer Patients Undergoing MRI Scans and a Relevant Mediator","Inclusion Criteria:\n\n1. The subject is diagnosed with cancer;\n2. The subject is between 18- 60 years old;\n3. The subject understands Mandarin, Cantonese, or English;\n4. The subject did not use medication for sedatives, anxiolytics, and\u002For sleep aids;\n5. The subject is awake without cognitive disorders;\n6. the subject rates more than 0 on the 0-10 VAS for anxiety;\n7. The subject has finished primary school level education.\n\nExclusion Criteria:\n\n1. The subject withdraws the MRI scan;\n2. The subject needs other intervention(s) to complete the scan;\n3. The subject has hearing and\u002For visual impairments;\n4. The subject has a history of a severe somatic psychiatric disease or clinically diagnosed mental disorders.","60 Years",{"count":105,"type":20},80,[23],"The primary objective of this study is to examine the effects of a music therapy protocol on improving anxiety, symptom distress, and relaxation among cancer patients who are going through MRI scanning. Physiological data, such as pulse rates and respiration rates will be collected. Furthermore, data about scanning efficiency will be collected to assess if scanning efficiency is affected by the protocol implementation. The secondary study objective is to assess whether or not there is a relationship between patient attention to music during the intervention process and the changes in anxiety, symptom distress, and relaxation.",[109],"Psycho-Oncology",[111,112,113,114,115],"MRI","Anxiety","Symptom distress","Relaxation","Music therapy","2024-12-31",{"date":118,"type":38},"2025-01-01",{"date":120,"type":38},"2021-11-09",{"date":122,"type":20},"2026-01-10",{"name":44,"class":45},""]